Patents by Inventor Michael Shultz

Michael Shultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089597
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: March 24, 2022
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Publication number: 20210309663
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: October 7, 2021
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Patent number: 10975080
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Publication number: 20190185475
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 20, 2019
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Patent number: 8841291
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Leslie Wighton McQuire, Michael Shultz, Ruben Alberto Tommasi, Sven Weiler
  • Publication number: 20140031399
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Inventors: Leslie Wighton MCQUIRE, Olivier ROGEL, Michael SHULTZ, Ruben Alberto TOMMASI, Sven WEILER
  • Patent number: 8362063
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 29, 2013
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • Publication number: 20120258954
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 11, 2012
    Applicant: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
  • Patent number: 8222424
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
  • Publication number: 20110183964
    Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.
    Type: Application
    Filed: April 8, 2011
    Publication date: July 28, 2011
    Applicant: NOVARTIS AG
    Inventors: Michael SHULTZ, Christine Hiu-Tung CHEN, Young Shin CHO, Lei JIANG, Jianmei FAN, Gang LIU, Dyuti MAJUMDAR, Jianke LI
  • Publication number: 20110112076
    Abstract: The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).
    Type: Application
    Filed: July 13, 2009
    Publication date: May 12, 2011
    Inventors: Leslie Wighton McQuire, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi, Sven Weiler
  • Publication number: 20110060009
    Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of use compounds of Formula I in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 10, 2011
    Inventors: Clinton A. BROOKS, Christine Hiu-Tung CHEN, Young Shin CHO, Lei JIANG, Gang LIU, Michael SHULTZ
  • Publication number: 20110053925
    Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, ring A, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 3, 2011
    Inventors: Young Shin CHO, Lei JIANG, Michael SHULTZ, Christine Hiu-Tung CHEN, Gang LIU, Jianke LI
  • Publication number: 20110014186
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: March 23, 2009
    Publication date: January 20, 2011
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
  • Publication number: 20100022514
    Abstract: The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.
    Type: Application
    Filed: December 17, 2007
    Publication date: January 28, 2010
    Inventors: Young Shin Cho, Lei Jiang, Michael Shultz
  • Publication number: 20100008923
    Abstract: The invention relates to pharmaceutical compositions containing inhibitors of histone deacetylase and B vitamins and methods of use thereof, in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.
    Type: Application
    Filed: June 25, 2007
    Publication date: January 14, 2010
    Inventor: Michael Shultz
  • Publication number: 20090247547
    Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.
    Type: Application
    Filed: March 26, 2009
    Publication date: October 1, 2009
    Inventors: Michael SHULTZ, Christine Hiu-Tung Chen, Young Shin Cho, Lei Jiang, Jianmei Fan, Gang Liu, Dyuti Majumdar
  • Publication number: 20070160437
    Abstract: The present invention is directed to a helical drill configuration that allows substantially flat bottomed holes to be machined. At the cutting end of the body member, there are at least two cutting edges that are symmetrically oriented on opposing sides of the rotational axis of the drill. In an embodiment of the invention, first and second cutting edge portions form a continuous surface which provides strength and tool stability. The height of the second portions of each of the cutting edges remains relatively consistent along the horizontal for formation of a generally flat bottom hole. In the embodiment, a center point is defined by two sloped peak surfaces. A central straight chisel edge is formed by the intersection of the two sloped peak surfaces. The first cutting edge section extends from the chisel edge to the second cutting edge section. The first cutting edge section for both cutting edges is formed by symmetrically thinning the two peak surface.
    Type: Application
    Filed: November 28, 2006
    Publication date: July 12, 2007
    Applicant: Kennametal Inc.
    Inventors: Michael Shultz, Stephen George, Raymond Moring, David Ford
  • Publication number: 20070022724
    Abstract: A system, apparatus and method for detecting defects in a honeycomb body. The system and apparatus include a fixture adapted to hold the honeycomb body, a particulate fluid source, a pipe which defines a flow path between the particulate fluid source and a first end face of the honeycomb body thereby allowing particulate fluid to flow from the particulate fluid source to the first end face of the honeycomb body. The particulate fluid emerges at a second end face of the honeycomb body through defects, if any, in the honeycomb body where the positions of such defects may be monitored. The system and apparatus includes a flow straightener disposed in the flow path to minimize boundary layer influence of the pipe on the flow of the particulate fluid. A substantially uniform velocity flow profile is provided to the first end face of the honeycomb body.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 1, 2007
    Inventors: Patrick Gargano, Babak Raj, William Ryszytiwskyj, Michael Shultz, David Worthey, Leon Zoeller
  • Publication number: 20050135887
    Abstract: A twist drill including a cutting tip having a front flank face, a substantially cylindrical tool body extending rearwardly from the cutting tip, and a shank. The tool body includes a rotational axis therethrough and at least one flute formed on an outer peripheral surface thereof and extending to the front flank face. The at least one flute includes a first helical portion opening to the front flank face and a second helical portion extending from the rear end of the first helical portion toward the rear portion of the tool body. The second helical portion twists in a direction opposite of the first helical portion.
    Type: Application
    Filed: December 17, 2003
    Publication date: June 23, 2005
    Inventors: Bernhard Borschert, Jerome Hanna, Tilo Krieg, Larry Meenan, Michael Shultz